Ra­maswamy’s En­zy­vant scores a dou­ble-bar­reled FDA com­mit­ment to help hus­tle a rare dis­ease drug through its BLA

Love him or hate him — and there are plen­ty of peo­ple in both camps — Vivek Ra­maswamy’s com­pa­nies move fast.

Just a lit­tle more than three …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.